deferasirox
deferasirox is listed in the FDA National Drug Code directory with 31 NDC codes, marketed under brand names including Exjade, Deferasirox, Jadenu. Available dosage forms: tablet, for suspension, granule, tablet, film coated, powder.
Drug details
- Generic Name
- deferasirox
- Brand Names
- Exjade, Deferasirox, Jadenu, Deferasirox Oral Granules, deferasirox
- Application Number
- NDA021882
- Sponsor
- Novartis Pharmaceuticals Corporation
- NDC Codes
- 31
- Dosage Forms
- TABLET, FOR SUSPENSION, GRANULE, TABLET, FILM COATED, POWDER
- Routes
- ORAL
- Active Ingredients
- DEFERASIROX
Indications and Usage
1 INDICATIONS AND USAGE Exjade is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. 1.2 Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. 1.3 Limitations of Use The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established.